Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases

Journal of Immunology

Volumn 160, Issue 12, 1998, Pages 6195-6203

  Gillies, Stephen D ^a   Lan, Yan ^a   Wesolowski, John S ^a   Qian, Xiuqi ^a   Reisfeld, Ralph A ^b   Holden, Sylvia ^a   Super, Michael ^a   Lo, Kin Ming ^a  

^a Lexigen Pharmaceuticals Corp   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; IMMUNOMODULATION; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN TARGETING; SCID MOUSE;

ANIMALS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-2; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 0032526895     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Fisher, R. I., C. A. Coltman, J. H. Doroshow, A. A. Rayner, M. J. Hawkins, J. W. Mier, P. Wiernik, J. D. McMannis, and G. R. Weiss. 1988. Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells: a phase II clinical trial. Ann. Intern. Med. 108:518.
2. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, L. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:901.
3. Grillo-Lopez, A. J., D. G. Maloney, D. Bodkinu, R. I. Schilder, C. White, K. N. Foon, N. Janakiramen, J. Neidhart, J. Rosenberg, C. D. Shen, I. Royston, and R. Levy. 1994. IDEC-C2B8: initial phase II results in patients with B-cell lymphoma. J. Immunother. 16:236.
4. Becker, J. C., J. D. Pancook, S. D. Gillies, J. Mendelsohn, and R. A. Reisfeld. 1996. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. Natl. Acad. Sci. USA 93:2702.
5. Becker, J. C., J. D. Pancook, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin-2 therapy. J. Exp. Med. 183:2361.
6. Lode, H. N., R. Xiang, N. M. Varki, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld. 1997. Targeted interleukin-2 therapy of spontaneous neuroblastoma to bone marrow. J. Natl. Cancer Inst. 89:1586.
7. Xiang, R., H. N. Lode, C. S. Dolman, T. Dreier, N. M. Varki, X. Qian, K.-M. Lo, Y. Lan, M. Super, S. D. Gillies, and R. A. Reisfeld. 1997. Elimination of established murine carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57:4948.
8. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chang, R. Louden, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827.
9. Wong, H. L., D. E. Wilson, J. C. Jenson, P. C. Familletti, D. L. Stremlo, and M. Gately. 1988. Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell. Immunol. 111:39.
10. Trinchieri, G. 1993. Interleukin-12 and its role in the generation of Th1 cells. Immunol. Today 14:335.
11. Chan, S. H., B. Perussia, J. W. Gupta, M. Kobayashi, M. Pospicil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of IFN-γ production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173:869.
12. Martinotti, A., A. Stoppacciaro, M. Vagliani, C. Melani, F. Spreafico, M. Wysocka, G. Parmiani, G. Trinchieri, and M. P. Colombo. 1995. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with IL-12 genes. Eur. J. Immunol. 25:137.
13. Vagliani, M., M. Rodolfo, F. Cavallo, M. Parenza, C. Melani, G. Parmiani, G. Forni, and M. P. Colombo. 1996. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res. 56:467.
14. Varki, N. M., R. A. Reisfeld, and L. E. Walker. 1984. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res. 44:681.
15. Jones, P. T., P. H. Dear, J. Foote, M. S. Neuberger, and G. Winter. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522.
16. Gillies, S. D., E. B. Reilly, K.-M. Lo, and R. A. Reisfeld. 1992. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA 89:1428.
17. Gillies, S. D., K.-M. Lo, and J. Wesolowski. 1989. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J. Immunol. Methods 125:191.
18. Gillies, S. D., H. Dorai, J. Wesolowski, G. Majeau, D. Young, J. Boyd, J. Gardner, and K. James. 1989. Expression of anti-tetanus toxoid antibody in transfected murine myeloma cells. BioTechnology 7:799.
19. Huston, J. S., D. Levinson, M. Mudgett-Hunter, M.-S. Tai, J. Novotny, and M. N. Margolies. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85:5879.
20. Perez, M. S., and L. E. Walker. 1989. Isolation and characterization of a cDNA encoding the KS-1/4 epithelial carcinoma marker. J. Immunol. 142:3662.
21. Szala, S., M. Froelich, M. Scollon, Y. Kasai, Z. Steplewski, H. Koprowski, and A. J. Linnenbach. 1990. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc. Natl. Acad. Sci. USA 87:3542.
22. Miller, A. D., and G. J. Rosman. 1989. Redesign of retroviral vectors for gene transfer and expression. BioTechniques 7:980.
23. Corbett, T. H., D. P. Griswold, B. J. Roberts, J. H. Peckham, and F. M. Schabel. 1975. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay, with a note on carcinogen structure. Cancer Res. 35:2434.
24. Gillis, S., M. M. Ferm, W. Ou, and K. A. Smith. 1978. T-cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 120:2027.
25. Gately, M. K., R. Chizzonite, and D. H. Presky. 1995 Measurement of human and mouse interleukin 12. In Current Protocols in Immunology, Vol. 1. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. John Wiley & Sons, New York, pp. 6.16.1-6.16.15.
26. Mueller, B. M., C. A. Romerdahl, S. D. Gillies, and R. A. Reisfeld. 1990. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J. Immunol. 144:1382.
27. Gillies, S. D., D. Young, K.-M. Lo, and S. Roberts. 1993. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug. Chem. 4:230.
28. Harvill, E. T., J. M. Fleming, and S. L. Morrison. 1996. In vivo properties of an IgG3-IL-2 fusion protein: a general strategy for immune polentiation. J. Immunol. 157:3165.
29. Gately, M. K., R. R. Warrier, S. Honasoge, D. M. Carvajal, D. A. Faherty, S. E. Connaughton, T. D. Anderson, U. Sarmiento, B. R. Hubbard, and M. Murphy. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. J. Immunol. 6:157.
30. Iwanuma, Y., F.-A. Chen, N. K. Egilmez, H. Takita, and R. B. Bankert. 1997. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res. 57:2937.
31. Hayashi, H., K. Tanaka, F. Jay, G. Khoury, and G. Jay. 1985. Modulation of the tumorigenicity of human adenovirus-12-transformed cells by interferon. Cell 43:263.
32. Cesano, A., S. Visonneau, S. C. Clark, and D. Santoli. 1993. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J. Immunol. 151:2943.
33. Kelleher, C. A., G. G. Wong, S. C. Clark, P. F. Schendel, M. D. Minden, and E. A. McCulloch. 1988. Binding of iodinated recombinant human GM-CSF to the blast cells of acute myelogenous leukemia. Leukemia 2:211.
34. Kim, T. S., R. H. DeKruyff, R. Rupper, H. T. Maeker, S. Levy, and D. T. Umetsu. 1997. An ovalbumin-IL12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J. Immunol. 158:4137.
35. Lieschke, G. J., P. K. Rao, M. K. Gately, and R. C. Mulligan. 1997. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat. Biotechnol. 15:35.
36. Riethmuller, G., E. Schneider-Gadicke, G. Schlimok, W. Schmiegel, R. Raab, K. Hoffken, R. Gruber, H. Pichlmaier, H. Hirche, R. Pichlmayr, P. Buggisch, J. Witte, and German Cancer Aid 17-1A Study Group. 1994. Randomized trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma. Lancet 343:1177.
37. Moller, P., and G. J. Hammerling. 1992. The role of surface HLA-A,B,C molecules in tumor immunity. Cancer Surv. 13:101.
38. Li, W., K. Berencsi, S. Basak, R. Somasundaram, R. P. Ricciardi, E. Gonczol, J. Zaloudik, A. Linnenbach, H. Maruyama, P. Miniou, and D. Herlyn. 1997. Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J. Immunol. 159:763.